Immune Thrombocytopenic Purpura - the European Oncology ...

References
1. Cines DB, McMillan R: Management of adult idiopathic
thrombocytopenic purpura. Annu Rev Med 56:425-42, 2005.
2. Kaye J, Schoonen M, Fryzek J: ITP incidence and mortality in
UK general practice research database. Haematologica 92
(Suppl.1):280 (Abstract 0751), 2007.
3. Bussel J: Treatment of immune thrombocytopenic purpura in
adults. Semin Hematol 43 (3 Suppl 5):S3-10; discussion S18-9,
2006.
4. Stasi R, Evangelista ML, Amadori S: Novel thrombopoietic agents:
A review of their use in idiopathic thrombocytopenic purpura.
Drugs 68 (7):901-12, 2008.
5. Arnold J, Ouwehand WH, Smith GA, Cohen H. A young woman
with petechiae. Lancet 352:618, 1998.
6. Azuno Y, Yaga K, Sasayama T, Kimoto K. Thrombocytopenia
induced by Jui,
a traditional Chinese herbal medicine [Letter]. Lancet 354:304-5,
1999.
7. George J, et al.: Idiopathic thrombocytopenic purpura: a practice
guideline developed by explicit methods for the American Society
of Hematology [see comments]. Blood 88 (1):3-40, 1996.
8. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N
Engl J Med 346: 995-1008, 2002
9. Provan D, et al.: Activity and safety profile of low-dose rituximab
for the treatment of autoimmune cytopenias in adults.
Haematologica 92 (12):1695-8, 2007.
10. Godeau B, et al.: Rituximab efficacy and safety in adult
splenectomy candidates with chronic immune thrombocytopenic
purpura - results of a prospective multicenter phase 2 study.
Blood:Epub ahead of print, 2008.
11. Arnold DM, Dentali F, Crowther MA, et al. Systematic Review:
Efficacy and Safety of Rituximab for Adults with Idiopathic
Thrombocytopenic Purpura. Ann Intern Med. 2007;146(1):25-33.
12. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20
monoclonal a ntibody treatment for adults with chronic
idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-
957. Clinical trial.
13. Stasi R, Stipa E, Forte V, et al. Variable patterns of response
to rituximab treatment in adults with chronic idiopathic
thrombocytopenic purpura. Blood. 2002;99(10):3872-3873.
14. Kuter DJ, et al.: Efficacy of romiplostim in patients with chronic
immune thrombocytopenic purpura: a double-blind randomised
controlled trial. Lancet 371 (9610):395-403, 2008.
15. Newland C, et al.: Evaluating the long-term efficacy of
romiplostim (AMG 531) in patients with chronic immune
thrombocytopenic purpura (ITP) during an open-label extension
study. Haematologica 93 (Suppl.1):377 (Abstract 0945), 2008.
16. Bussel JB, et al.: Eltrombopag for the treatment of chronic
idiopathic thrombocytopenic purpura. N Engl J Med 357
(22):2237-47, 2007.
17. FDA Oncologic Drug Advisory Committee Briefing Document.
Promacta (Eltrombopag Tablets) http://www.fda.gov/ohrms/
dockets/AC/08/briefing/2008-4366b1-02-GSK.pdf. Accessed
July 21st 2008
18. Portielje JEA, et al.: Morbidity and mortality in adults with
idiopathic thrombocytopenic purpura. Blood 97 (9):2549-2554,
2001.
19. McMillan R, et al.: Self-reported health-related quality of life in
adults with chronic immune thrombocytopenic purpura. Am J
Hematol 83 (2):150-4, 2008.
20. Mathias SD, et al.: Impact of chronic Immune Thrombocytopenic
Purpura (ITP) on health-related quality of life: a conceptual model
starting with the patient perspective. Health Qual Life Outcomes
Feb 8;6:13, 2008
Update accreditation
• Diploma of Advanced Studies Berner Fachhochschule in Onkologiepflege, Lindenhof Schule, Bern
Switzerland, educational programme of study. For more information: www.lindenhof-schule.ch
• Chemotherapy course for oncology nurses, Estonian Oncology Nursing society, 14,15,16 April 2008,
educational event
• ESO “11 Internationales seminar: Onkologische pflege Fortgeschrittene Praxis”., September 2008,
educational event. For more information: www.oncoconferences.ch
newsletter fall 2008 -
27